MATERNAL911®

Severe Preeclampsia

Click the next button to continue...

Maternal 911 Education Systems, LLC
475 West Center St.
Ithaca, MI 48847
www.maternal911.com

Maternal 911 and Maternal 911 in Action contains information designed as an educational resource to aid practitioners in providing obstetric care and the use of this information is voluntary. This information should not be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. It is not intended to substitute for the independent professional judgement. Maternal 911 reviews the publication regularly, but may not reflect the most recent evidence.

Maternal 911 makes every effort to present accurate and reliable information. The Maternal 911 and Maternal 911 in Action are publications provided 'as is' without any warranty of accuracy, reliability or otherwise, either express or implied. Maternal 911 does not guarantee, warrant, or endorse the products or services of any firm, organization, or person. Neither co-founder nor any officers, directors, members, employees, participants or agents will be liable for any loss, damage or claim with respect to liabilities, including direct, special, indirect, or consequential damages, incurred in connection with this publication or reliance on the information presented.

Data from completing the modules may be used in research and publications with privacy maintained.

MATERNAL911®

Course Description:

Hypertensive disorders in pregnancy remain one of the leading causes of maternal death. The Maternal 911 Severe Preeclampsia module will give you a basis of knowledge to better recognize and treat preeclampsia. This knowledge base will help with communication to the patient and her family. The goal would be to increase the maternal safety for the unit where she will undergo care and delivery.

Approximate Time to Complete: 120 minutes

Click here to download a print version of this course.



The purpose of this module is for the participant to:

- Explain criteria for preeclampsia, severe preeclampsia, and eclampsia.
- Identify risks associated with causing preeclampsia.
- Recognize the signs and symptoms of worsening preeclampsia so prompt health care delivery can be implemented.
- Describe the pathogenesis of preeclampsia.
- Identify clinical features and pathophysiology by organ system.
- Describe the medications used for resuscitation and how they may affect the woman and expected outcomes.



Preeclampsia is a multi-system progressive disorder characterized by the new onset of hypertension and proteinuria, or hypertension and end-organ dysfunction with or without proteinuria, in the last half of pregnancy or postpartum, often in a previously normotensive woman.

Criteria for Diagnosing Preeclampsia

Preeclampsia is defined as systolic blood pressure (BP) > 140 mmHg or diastolic BP > 90 mmHg on two occasions, at least four hours apart, after 20 weeks of gestation in previously normotensive woman with proteinuria >0.3 grams in a 24-hour urine specimen or protein(mg/dL)/creatinine (mg/dL) ratio > 0.3.

Severe preeclamspsia is diagnosed when systolic BP is > 160 mmHg or diastolic BP is > 110 mmHg, confirmation within minutes is sufficient **AND** proteinuria >0.3 grams in a 24-hour urine specimen **or** protein(mg/dL)/creatinine (mg/dL) ratio > 0.3.

Protein dipstick 1+ if a quantitative measurement is unavailable.

It is important to note the collection of 24 hour urine should not delay treatment.

The protein creatinine ratio is calculated with this formula:
(urine protein x 0.88) + (urine creatinine)

An online calculator can be found at:
https://www.easycalculation.com/medical/urinaryprotein.php

MATERNAL911®

Urinary Proteins Excretion C

easycalculation.com

Urine Protein	
Urine Creatinine	
Uprot / Ucreat	
Estimated 24 hour urine protein	

Eclampsia is diagnosed when grand mal seizures have occurred in a woman with no history of neurological conditions.

Seizures can occur before, during, or after delivery of the fetus.

Preeclampsia

- Is estimated to occur in 4.6% of pregnancies worldwide [1].
- The prevalence of preeclampsia in the United States (U.S.) is about 3.4% but 1.5- to 2-fold higher in first pregnancies [2].
- In one population-based study, onset of preeclampsia ≥ 34 weeks is more prevalent than early onset < 34 weeks [3].

Eclampsia

- Occurs in 2 to 3% of women with severe features of preeclampsia not receiving anti-seizure prophylaxis and up to 0.6% of women with preeclampsia without severe features (previously referred to as "mild" preeclampsia) [4].
- The incidence of eclampsia has been stable at 1.6-10 cases per 10,000 deliveries in developed countries [5-10].
- In developing countries, however, the incidence varies widely from 6 to 157 cases per 10,000 deliveries [11-13].



Preeclampsia and eclampsia is 1 of the 4 leading causes of maternal death in the United States, along with hemorrhage, cardiovascular conditions, and thromboembolism [14-16].

Approximately one maternal death per 100,000 live births is due to preeclampsia or eclampsia with a case fatality rate of 6.4 deaths in 10,000 cases [17-19].

It is imperative to educate women during their pregnancy of signs and symtpoms involved with preeclampsia and empower her to reach out for help if these occur.

Maternal and fetal placental factors are involved in the pathophysiology of preeclampsia with both affecting the severity of the disease.

Realize that placental tissue is needed for the disease to occur, but not a fetus [20-22]. Upon delivery of the placenta, preeclampsia is always cured within days to weeks.

Research examining various gestational ages of human placentas with normal pregnancies compared to those with preeclampsia has led to an understanding of the pathological changes in the uteroplacental circulation relevant to preeclampsia.

It has been found that the spiral artery remodeling and trophoblastic invasion have defects leading to characteristic hypertensive disorders of pregnancy and fetal growth restriction [23,24].

It is clear that defects in spiral artery remodeling and trophoblast invasion, two related but separate processes, are characteristic of hypertensive disorders of pregnancy and fetal growth restriction [23,24].

Defects in spiral artery remodeling and trophoblast invasion result in impaired placentation and placental ischemia, the primary events leading to placental release of soluble factors causing systemic endothelial dysfunction in the preeclamptic phenotype.

Hypoperfusion appears to be both a cause and a consequence of abnormal placental development.

With the progression of pregnancy, the abnormal uterine vasculature is unable to accommodate the normal rise in blood flow to the feto-placental unit, resulting in hypoperfusion as gestational age increases [25-27].

Late placental changes consistent with ischemia include:

- Atherosis (lipid-laden cells in the wall of the arteriole)
- Fibrinoid necrosis
- Thrombosis
- Sclerotic narrowing of arterioles
- Placental infarction [28-32]

These defects in placentation are associated with development of multiple adverse pregnancy outcomes, including [153]:

- 2nd trimester fetal death
- Placental infarcts
- Abruptio placentae
- Preeclampsia with or without intrauterine growth restriction
- Intrauterine growth restriction without maternal hypertension
- Premature rupture of membranes (PROM)
- Preterm labor (PTL) [153]

Critical components in the pathogenesis of preeclampsia include:

- Hypoperfusion
- Hypoxia
- Ischemia

The release of factors into the maternal blood stream alters the maternal endothelial cell function, leading to characteristic systemic signs and symptoms of preeclampsia elaborating the hypoperfusion, hypoxemia, and ischemia. [33-39].

The pathogenesis of preeclampsia has critical components of hypoperfusion, hypoxemia, and ischemia, leading to a variety of factors being released into the maternal blood stream—altering maternal endothelial function and leading to characteristic systemic signs and symptoms of preeclampsia [33-39].

Hypoperfusion becomes more pronounced as pregnancy progresses, since the abnormal uterine vasculature is unable to accommodate the normal rise in blood flow to the fetus/placenta with increasing gestational age [25-27].

It is unknown why the normal sequence of events, in development of the uteroplacental circulation, does not occur in some pregnancies.

The following are suspected to play a role:

- Vascular
- Environmental
- Immunological
- Genetic factors [40]

Delivery of the placenta is the cure for preeclampsia [40].

It is imperative to the health of the mother and fetus to communicate worsening signs and symptoms of worsening or severe preeclampsia to the provider if they are present:

- Headache
- Increasing BP
- Altered consciousness: restless, agitation, hallucinations, lethargy, confusion
- Visual disturbances: floaters, blurred vision, spots, blind spots
- Upper abdominal pain
- Urine output < 30mL/hour
- Shortness of breath
- Complaints of chest pain
- Pulse oximetry < 95%
- Cough
- Tachypnea > 26 breaths/min
- Tachycardia > 100 bpm
- Adventitious breath sounds
- Eclamptic seizure
- Magnesium toxicity [163]

This link provides a tool for preeclamspia early recognition (PERT) to help: https://www.health.ny.gov/publications/2036.pdf

New York State Department of Health **Preeclampsia Early Recognition Tool (PERT)**

ASSESS	NORMAL (GREEN)	WORRISOME (YELLOW)	SEVERE (RED)
Awareness	Alert/oriented	• Agitated/confused • Drowsy • Difficulty speaking	• Unresponsive
Headache	None	• Mild headache • Nausea, vomiting	• Unrelieved headache
Vision	None	• Blurred or impaired	• Temporary blindness or blind spots
Systolic BP (mm Hg)	100-139	140-159	≥160
Diastolic BP (mm Hg)	50-89	90-109	≥110
HR	61-110	111-129	≥130
Respiration	11-24	25-30	<10 or >30
SOB	Absent	Present	Present
O2 Sat (%)	≥95	91-94	≤90
Pain: Abdomen or Chest	None	• Nausea, vomiting • Chest pain • Abdominal pain	• Nausea, vomiting • Chest pain • Abdominal pain
Fetal Signs	• Category I • Reactive NST	• Category II • IUGR • Non-reactive NST	• Category III
Urine Output (ml/hr)	≥50	30-49	≤30 (in 2 hrs)
Proteinuria (Level of proteinuria is not an accurate predictor of pregnancy outcome)	Trace	• ≥ 1+** • ≥300mg/24 hours	• 3+ or greater on 2 samples 4 hours apart*** • ≥ 5 Gms/24 hours***
Platelets	>100	50-100	<50
AST/ALT	normal	1-<2x normal	2x normal or greater
Creatinine	≤0.8	0.9-1.1	≥1.2
Magnesium Sulfate Toxicity	• DTR +1 • Respiration 16-20	• Depression of patellar reflexes	• Respiration <12

GREEN = NORMAL

Proceed with Protocol

YELLOW = WORRISOME

Increase assessment frequency

# Triggers	TO DO
1	• Notify provider & charge nurse
≥2	• Notify provider & charge nurse • In-person evaluation • Order labs/tests • Anesthesia consult • Consider magnesium sulfate • Supplemental oxygen

** Physician should be made aware of worsening or new-onset proteinuria.

RED = SEVERE

Trigger: 1 of any type listed below	TO DO
1 of any type	• Notify provider & charge nurse • Immediate evaluation • Transfer to higher acuity level • 1:1 staff ratio
Awareness	• Consider Neurology consult
Headache	• CT Scan
Visual	• R/O SAH/Intracranial hemorrhage
BP	• Labetalol/hydralazine in 15 minutes • Magesium sulfate loading or maintenance infusion
Chest pain	• EKG, Consider CT angiogram
Respiration	• O2 at 10L per rebreather mask
SOB	• R/O pulmonary edema
O2 SAT	• Chest x-ray

*** Results signify massive proteinuria and physician should be notified. Although massive proteinuria has been eliminated from the consideration of preeclampsia as "severe", physician should be made aware of worsening or new-onset proteinuria.

New York State nyspQc Perinatal Quality Collaborative

NEW YORK STATE Department of Health

Citation: Maurice L. Druzin, MD, Laurence E. Shields, MD, Nancy L. Peterson, RNC, PNNP, MSN, Kathryn Melsop, MS, Valerie Cape, BS, BA. Preeclampsia Toolkit: Improving Health Care Response to Preeclampsia (California Maternal Quality Care Collaborative Toolkit to Transform Maternity Care) Developed under contract #11-10006 with the California Department of Public Health; Maternal Child, and Adolescent Health Division; Published by the California Maternal Quality Care Collaborative, August 2013.

The funding for the development of the toolkit was provided by Federal Title V block grant funding from the California Department of Public Health: Maternal, Child and Adolescent Health Division and Stanford University.

Cardiopulmonary

Hypertension may be the earliest clinical finding of preeclampsia and is the most common clinical indication to the presence of the disease.

Some women may develop hypertension rapidly or before 34 weeks of gestation or in the postpartum period.

The BP usually rises gradually to ≥140/90 mmHg.

- Often in the third trimester and after the 37th week of gestation [33].

A systolic BP of ≥160 mm Hg or diastolic blood pressure of ≥110 mm Hg on two occasions at least four hours apart is a feature of severe disease [4].

Intravascular Volume

A reduced volume is suspected to result from vasoconstriction due to enhanced responses of vasocative substances.

Intravascular volume may be reduced when severe features of preeclampsia are present.

The reduction in intravascular volumes has never been fully understood to date.

Edema

May be due to capillary leaking or represent "overfill" edema.

Edema itself does not indicate developing preeclampsia; many pregnant women have edema.

Further evaluation for preeclampsia is needed when the pregnant woman develops sudden, rapid weight gain of more than 5 pounds per week with facial edema.





CARDIAC FUNCTION

The myocardium is not directly affected, but the heart responds to physiologic changes caused by preeclampsia.

- Left ventricular ejection fraction usual remains within normal limits (WNL) [43].
- Left ventricular longitudinal, circumferential, and radial systolic strain have been observed [44].
- The reduction in left ventricular performance is a physiologic response to increased afterload [43-45].

Click through all 4 slides before moving on to the next page.



CARDIAC FUNCTION

Systolic strain is present in preeclamptic women compared to pregnant women with non-proteinuria hypertenstion.

- Therefore, other factors may play a role [44].

High cardiac afterload that occurs in preeclampsia is associated with elevated cardiac filling pressures with a 4-fold higher concentration of natriuretic peptides in these women compared to women with normal BP or with chronic hypertension [45]. Elevated cardiac filling pressures with a 4-fold higher concentration of natriuretic peptides in women with preeclampsia who have normal BP or have chronic hypertension [45].

Click through all 4 slides before moving on to the next page.



CARDIAC FUNCTION

Severe Preeclampsia

Can be associated with a highly variable hemodynamic profile [45-50].

- A small subgroup of women develops myocardial damage or diastolic dysfunction [50].

Click through all 4 slides before moving on to the next page.



CARDIAC FUNCTION

Severe Preeclampsia

Troponin I levels should be evaluated if the woman complains of chest pain or new electrocardiogram (EKG) changes are observed [51,52].

Preeclampsia is not associated with elevated troponin levels in the absence of cardiac disease [53].

Pulmonary Edema

May be the presenting feature with severe preeclampsia:

- The etiology is multifactorial [54-57].
- Pulmonary vascular hydrostatic pressure is elevated compared with plasma oncotic pressure that may cause edema.
- Edema is present more in the postpartum period.
- Not all preeclamptic women with pulmonary edema demonstrate these features.

Other causes may include capillary leak, left sided heart failure, and unknown volume overload.



RENAL FUNCTION



Glomerular filtration rate (GFR) decreases by 30 to 40% in preeclampsia compared with pregnant normotensive women.

Renal plasma flow decreases, but to a lesser degree.

Click through all 6 slides before moving on to the next page.

RENAL FUNCTION



Plasma creatinine is normal or slightly elevated (1.0 to 1.5 mg/dL).

Creatinine > 1.1mg/dL or doubling indicates severe disease.

- This is caused by renal vasoconstriction and sodium retention due to reduced plasma volume and systemic vasoconstriction.

Urine output may decrease to <500mL/24 hours.

- This is considered oliguria and is a feature of severe preeclampsia.

Click through all 6 slides before moving on to the next page.

RENAL FUNCTION



Hyperuricemia

- The cause is related to the reduction in GFR.
- Decreased tubular secretion or increased reabsorption.
- This is suspected when serum uric acid is greater than expected for mild reductions in GFR [67].

Click through all 6 slides before moving on to the next page.



RENAL FUNCTION

The role of serum uric acid levels remains controversial as a predictor of complications associated with preeclampsia [68, 69].

An international prospective study of women with preeclampsia demonstrated that serum uric acid, based upon gestational age:

- Is not clinically useful in predicting adverse maternal outcomes.
- Is useful in predicting perinatal outcomes [70].

Click through all 6 slides before moving on to the next page.



RENAL FUNCTION

Urine sediment is generally benign.

Histology changes performed via kidney biopsies and in postmortem specimens of women who died of eclampsia are termed glomerular endotheliosis.

Specimens show:

- Endothelial cell swelling
- Loss of fenestrations
- Occlusion of capillary lumens [71]

Click through all 6 slides before moving on to the next page.



RENAL FUNCTION

Glomerular Endotheliosis

- Shares histologic features with non-preeclamptic thrombotic microangiopathies [71]
- Rarely is this present without proteinuria
- Nonpregnant women [72,73]

Hematologic

The most common coagulation abnormality in preeclampsia is thrombocytopenia.

Microangiopathic endothelial injury leads to the formation of platelet and fibrin thrombi in the microvasculature.

Thrombocytopenia occurs due to accelerated platelet consumption, however, immune mechanisms may also play a role [74].

A platelet count less than 100,000/microl upstages the preeclampsia to severe preeclampsia.

The prothrombin time (PT), partial thromboplastin time (PTT) and firbrinogen concentrations are not affected unless additional complications occur, such as placental abruption or severe liver dysfunct on [75].

HEMATOLOGIC

When hemolysis and reduced plasma volume are both present the hematocrit may be normal.

White blood cell (WBC) count may be slightly elevated due to neutrophilia.

The accelerated consumption of platelets leads to thrombocytopenia

- Immune mechanisms are thought to also play a role [74]

A platelet count of < 100,000/microl moves the patient to severe preeclampsia.

Concentrations of the following are not affected unless abruptio placenta or severe liver dysfuntion is also present:

- Prothrombin time (PT)
- Partial thromboplastin time (PTT)
- Fibrinogen [75]

HEMATOLOGIC

HEPATIC



Histologic findings observed in the livers of preeclamptic women [76, 77]

- Periportal fibrin deposits
- Sinusoidal fibrin deposits
- Microvesicular fat deposits

Reduced hepatic blood flow can lead to:

- Ischemia
- Periportal hemorrhage

Click through all 5 slides before moving on to the next page.

HEPATIC



Clinical Manifestations

- Right upper quadrant (RUQ) or epigastric pain
- Elevated transaminase levels (ALT)
- Coagulopathy
- Subcapsular hemorrhage
- Hepatic rupture
- Nausea and vomiting may occur

These hepatic changes place the woman in the severe preeclampsia category.

Click through all 5 slides before moving on to the next page.

HEPATIC



Epigastric pain is one of the cardinal symptoms of severe preeclampsia.

The pain is described as severe, constant pain that usually begins at night.

Maximal pain is felt in the low retrosternum or epigastrium regions.

Pain may radiate to the right hypochondrium or back [78].

Click through all 5 slides before moving on to the next page.

HEPATIC



Epigastric Pain

Thought to be related to stretching of the Glisson's capsule due to hepatic swelling or bleeding.

May be the only symptom she has which may lead to the suspicion of gastroesophageal reflux (GERD).

- GERD is common for pregnant women and occurs more often at night.

Palpation of the liver may cause her discomfort.

Click through all 5 slides before moving on to the next page.

HEPATIC



Transient diabetes insipidus has been reported in preeclampsia with hepatic dysfunction; but is a rare occurrence.

Further discussion of diabetes insipidus is beyond the scope of this program.

Central Nervous System (CNS)

Central nervous system manifestations of preeclampsia include:

- Headache
- Visual symptoms
- Generalized hyperreflexia
- Sustained ankle clonus

CNS

Headache may be:

- Temporal
- Frontal
- Occipital
- Diffuse [79, 80]

Pain described as:

- Throbbing
- Pounding
- Piercing

The headache is not relieved with over-the-counter (OTC) analgesics.

CNS - Eye

Visual symptoms are caused by retinal arteriolar spasm [81].

Symptoms include:

- Blurred vision
- Flashing lights or sparks (photopsia)
- Scotomata (dark area or gaps in the visual field [82-84]
- Diplopia (blindness in one eye)
- Cortical blindness is rare and typically transient [85]

CNS - Eye

Blindness due to the following pathology may be permanent [86]:

- Retinal artery occlusion
- Retinal vein occlusion
- Retinal detachment
- Optic nerve damage
- Retinal artery spasm
- Retinal ischemia

CNS - Seizures

When a seizure occurs in a woman with preeclampsia, it signifies worsening of the condition. She is given the diagnosis of eclampsia.

- 1 in 400 women with preeclampsia without severe features develop eclamptic seizures [4].
- 1 in 50 severely preeclamptic women will develop eclamptic seizures [6-12].



CNS - Seizures

Histopathological findings in women who have progressed to eclampsia include:

- Hemorrhage
- Petechiae
- Cerebral edema
- Vasculopathy
- Ischemic brain damage
- Microinfarcts
- Fibrinoid necrosis [87]



CNS – Cerebrovascular Manifestations

Are poorly understood.

Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) findings may include:

- Cerebral edema
- Cerbral ischemia
- Hemorrhagic changes [88, 89]

CT or MRI findings:

- Identify generalized endothelial cell dysfunction
- May result from loss of cerebrovascular autoregulation
- Posterior reversible leukoencephalopathy syndrome (PRES) [90, 91]
- PRES is associated with severe hypertension but can progress quickly in a woman who has endothelial damage [92]

Clinical Features of the Renal System

The kidney is the organ most likely to manifest endothelial injury related to preeclampsia.





Renal - Proteinuria

The most common cause of severe proteinuria in pregnant women is preeclampsia.

Click here to see more information.

Proteinuria is defined as:

- >0.3 grams of protein in a 24-hour specimen.
- Persistent 1+ (30mg/dL) on dipstick.
- A random protein to creatinine ratio ≥0.3mg protein/mg creatinine.
- Most often women with preeclampsia will have <5g/day of protein.
- Levels > 10g/day may be seen [55-63].

Proteinuria

- As preeclampsia progresses, typically proteinuria worsens, but may be a late finding [64, 65].
- Is caused by impaired integrity of the glomerular filtration barrier.
- The protein excretion increases with hypofiltration that occurs due to altered tubular handling of filtered proteins [66].



CNS – Stroke

Leading cause of death or disability of severe preeclampsia or eclampsia

- Severe preeclampsia or eclampsia is present in 36% of pregnancy-associated stroke [93].

Most strokes in this setting are:

- Hemorrhagic
- Preceded by severe headache
- Severe and fluctuating BPs



CNS – Stroke

Eclamptic seizures do not occur in all cases.

Risk factors for hemorrhagic stroke in women with preeclampsia include:

- Severe, persistent hypertension
- Systolic BP persistently >160mmHg and/or
- Diastolic BP persistently >110mmHg
- Severe headache
- Seizures



Lowering BP may reduce the risk.

However, criteria for persistent hypertension and timing of initiation of acute antihypertensive therapy after 15 minutes, 30 minutes, or >60 minutes to prevent stroke are unclear.

Other Maternal Symptoms

- Acute pancreatitis is rare [96]
- Change in lipid metabolism [94,95]
- Elevated total cholesterol
- Elevated triglyceride levels

Fetus

Fetal Growth Restriction:

- Severe and early onset of preeclampsia affects birth weight [97].
- Late onset of preeclampsia is associated with higher than average birth weight [98-102].
- Related to greater placental perfusion [103].
- Due to elevated cardiac output observed with late onset of preeclampsia.

Oligohydramnios

Early Onset Severe Preeclampsia Increases the Risk of:

- Fetal death
- Perinatal death
- Severe neonatal morbidity [104,105]

A secondary result of fetal or maternal complications may indicate preterm delivery.

Preeclampsia does not accelerate fetal maturation.

In preeclamptic women with age-matched normotensive controls, frequency of the following neonatal morbidities is not increased:

- Neonatal respiratory distress
- Intraventricular hemorrhage
- Necrotizing enterocolitis (NEC) [106]

Abruptio Placenta

Occurs in <1% of women with preeclampsia without severe features.

Occurs in 3% of women who have severe features [107].

Table 1 and Table 2 review features of preeclampsia with adverse and severe features.

System	Adverse Event	Severe Event
Central Nervous System (CNS)	Severe headache, headache that persists and progresses despite analgesia, altered mental status. Visual symptoms: • Photopsia (presence of perceived flashes of light) • Scotomata (partial alteration in the field of vision) • Cortical blindness • Retinal vasospasm	• Eclampsia • Posterior reversible leukoencephalopathy (PRES) • Cortical blindess or retinal detachment • Glasgow coma scale <13 • Stroke, Transient Ischemic Attack (TIA), or Reversible Neurological Deficit <48hr
Cardiopulmonary	• Chest pain • Dyspnea • Oxygen saturation <97%	• Uncontrolled severe hypertension. • Systolic BP ≥160mmHg or diastolic BP ≥110mmHg on two occasions at least four hours apart while the patient is on bedrest unless the patient is on antihypertensives.
Hematology	• Elevated WBC count • Elevated INR or aPTT • Low platelet count <100,000 platelets/microL	• Platelet count <50x100/L • Transfusion of any blood product

System	Adverse Event	Severe Event
Renal	• Elevated serum creatinine • Elevated serum uric acid	• Acute kidney injury, no prior renal disease and a creatinine >150μM • Need for dialysis
Hepatic	• Nausea or vomiting • Right upper quadrant (RUQ) or epigastic pain unresponsive to medication and not accounted for by an alternative diagnosis or doubling transaminase concentration • Elevated serum Asparate aminotransferase (AST), Alanine aminotransferase (ALT), Lactate dehydrogenase (LDH), bilirubin or low plasma albumin	• Hepatic dysfunction; INR >2 in absence of disseminated intravascular coagulation (DIC) or warfarin • Hepatic hematoma or rupture
Feto-placental	• Abnormal fetal heart rate (FHR) • Intrauterine growth restriction (IUGR) • Oligohydramnios • Absent or reversed end-diastolic flow by Doppler velocimetry	• Abruption with evidence of maternal or fetal compromise • Reverse ductus venosus • Stillbirth

A critical factor in reducing maternal mortality is early recognition and treatment of worsening signs and symptoms of preeclampsia. Health care providers often fail to recognize and respond to clinical signs and symptoms in a timely manner.

In fact, missed vital sign 'triggers' occurred in 60% of preeclampsia deaths [161]. These cases demonstrate an overall lack of critical thinking.

This module will help with the development of this critical thinking, but each center must develop a process for recognition and response to patient's deteriorating conditions with written criteria describing early warning signs and indicating when to seek further assistance [162].

Risk Factors for Preeclampsia

Hypertension in pregnancy carries risk factors alone but also elevates the risk for:

- Cerebrovascular complications
- Cardiac complications
- Renal complications

These complications may occur during the pregnancy and immediately postpartum.

Women who develop preeclampsia are at increased risk for:

- Placenta abruption
- Acute kidney injury
- Cerebral hemorrhage
- Hepatic failure or rupture
- Pulmonary edema
- Disseminated intravascular coagulation (DIC)
- Eclampsia

Risk Factors for Preeclampsia

Nulliparity or first on-going pregnancy

Exposure to paternal antigens is associated with the pathogenesis of preeclampsia. The primigravid woman, in theory, may be at risk due to limited exposure [108].

Risk Factors for Preeclampsia are Related to:

- Ethnicity: Nordic, Black, South Asian, and Pacific Island
- Lower socioeconomic class
- Age >40 or <18
- Diabetes mellitus and chronic hypertension have heightened occurrence in older women [108].
- Research is ongoing whether adolescents have a higher risk of preeclampsia [108].



Other Risk Factors Associated with Preeclampsia May Include:

- Preeclampsia in a previous pregnancy
  - The severity of preeclampsia strongly impacts this risk.
- In 25-65% of subsequent pregnancies, women who had severe features of preeclampsia in the second trimester of a previous pregnancy developed recurrence of this condition [110-113].
- In comparison, there is only a 5-7% recurrence is subsequent pregnancies when women do not have severe features of preeclampsia in their first pregnancy [114,115].
- Women who had a normotensive first pregnancy develop preeclampsia in less than 1% of second pregnancies [108].

Other research indicates when a woman has a history of preeclampsia she has a **7-fold increase** risk of developing preeclampsia in the subsequent pregnancy [108].




- Most cases of preeclampsia occur without any family history.
- However, preeclampsia may have a hereditary aspect when a first degree relative has had preeclampsia [108].

Click each image to learn more.




A mother or sister having had preeclampsia increases the risk in a woman's first pregnancy for developing preeclampsa by **2- to 5-fold** compared to a woman with no family history [116-119].

Click each image to learn more.




The paternal contribution to the fetal genes can affect the defective placentation, thus contributing to subsequent preeclampsia [120].

Click each image to learn more.




Preeclampsia is more likely to develop in the spouses of men who were the product of the pregnancy complicated by preeclampsia, compared to those without this history [121,122].

The development of preeclampsia is more likely when a woman becomes pregnant by a man who has fathered a preeclamptic pregnancy with another woman [123].

The risk of preeclampsia is increased in a first pregnancy or short duration of exposure to her partner.

Further risks exist with:

- Chronic hypertension
- Chronic renal disease
- End stage renal disease, which is a long term risk for women with preeclampsia [124,125].

Risk Factors for Preeclampsia

Antiphospholipid antibody syndrome (APS) or inherited thrombophilias:

- The most concerning types of antiphospholipid antibodies (aPL) to obstetricians are lupus anticoagulants (LA) and anticardiolipen antibodies (aCL) [126].
- Risk for later miscarriages and/or thromboembolic complications involve the anti-beta-2-glycoprotein-1 antibodies [127].

Risk Factors for Preeclampsia

Thrombophilias

- Factor V Leiden
- Protein S
- When women with APS become pregnant they have a 5-12% occurrence, while the general obstetrical population has a 0.025 - 0.10% rate of preeclampsia to develop [128,129].

Vascular or Connective Tissue Disease

Risk Factors for Preeclampsia

Preexisting Medical Conditions

- Pregestational diabetes
- Underlying renal or vascular disease
- High plasma insulin levels/insulin resistance
- Abnormal lipid metabolism [123]
- BP > 130/80 mmHg at first prenatal visit or first visit diastolic BP > 90 [130]
- aPL antibodies [129]
- Body mass index (BMI) > 26.1, overweight [130]
- Chronic kidney disease
- Risk is associated with the reduction of GFR and presence or absence of hypertension [130]
- Renal disease or first visit proteinuria
- Diabetes mellitus (DM)
- Collagen vascular disease
- Periodontitis

Risk Factors for Preeclampsia

- Increased prepregnancy triglycerides
- Family history of early-onset cardiovascular disease
- Preeclampsia occurs at higher rates with multi-order gestations [132]:
  - Twins
  - Triplets
  - Quadruplets



Risk Factors for Preeclampsia

- Hydrops fetalis
- Unexplained fetal growth restriction
- Woman, herself, was small for gestational age
- Fetal growth restriction, abruptio placenta, or fetal demise in a previous pregnancy
- Pregnancy interval of < 2 years or > 10 yrs
- Susceptibility genes

Risk Factors Cont'd

- Non-smoker [11]
  - Evidence has shown smoking **decreases** the risk of preeclampsia
- Cocaine and/or methamphetamine use
- Reproductive technology to conceive
- Gestational trophoblastic disease
- History of hydatidiform mole
- Infection:
  - Urinary tract infection (UTI)
  - Periodontal disease

Risk Factors for Preeclampsia

- Systolic BP >120mmHg
- Abnormal maternal serum screen (MSS)
- Abnormal uterine artery doppler velocimetry
- Excessive weight gain in pregnancy
- Cardiac output >7.4L/min
- Elevated uric acid
- Investigational laboratory marker

Women with chronic hypertension may have good pregnancy outcomes; however, a at higher risk for having pregnancy complications compared to a normotensive woman.

Adverse pregnancy outcomes are generally directly related to the degree of hypertension and organ involvement.

The History and Physical Examination Should Evaluate the Patient for:

- Persistent and/or severe headaches
- Upper abdominal or epigastric pain
- Nausea or vomiting
- Dyspnea
- Altered mental status
- Visual abnormalities, such as:
  - Scotomata
  - Photophobia
  - Blurred vision
  - Temporary blindness

The minimum post-diagnostic testing:

- Platelet count
- Serum creatinine
- Serum aspartate aminotransferase (AST)
- Serum alanine transaminase (ALT)
- Obstetrical ultrasound
  - Fetal weight
  - Amniotic fluid volume (AFV)
- Fetal assessment
  - Non-stress test (NST) or Biophysical profile (BPP)

Additional Testing to Consider:

- Blood smear
- Serum lactate dehydrogenase (LDH)
- Bilirubin concentrations:
  - Microangiopathic hemolysis is suggested by elevated LDH and indirect bilirubin levels and red cell fragmentation (schistocytes or helmet cells) on peripheral blood smear.
  - Hemoconcentration occurs in preeclampsia, but hemolysis, if present, can decrease the hematocrit to normal or anemic levels.
- Coagulation function tests:
  - Prothrombin time
  - Activated partial thromboplastin time
  - Fibrinogen concentration
- Usually coagulation function tests are normal in patients without thrombocytopenia or liver dysfunction; therefore, they are not checked routinely [134].

Management includes evaluation and decision to treat hypertension during pregnancy, considering the risks and benefits for the mother and her fetus to prevent poor outcomes.

Goals in health care delivery are to prevent:

- Organ damage
- Seizures
- Cerebral vascular accidents (CVA)
- Deep vein thrombosis (DVT)
- Maternal and/or fetal death

Fetal complications can be the result of placenta abruption and/or Fetal Growth Restriction (FGR), which can result in death.

Treatment of severe hypertension is necessary when the systolic BP ≥160 mmHg and/or diastolic BP ≥110 mmHg, to reduce the risk of maternal stroke.

The goal is lower the BP, not to normal, but to a less severe range between 140-160/90-100mmHg.

Antihypertensive Therapy

- All antihypertensive drugs cross the placenta.
- There are no randomized trials suggesting which drug is recommended.
- Data is inadequate to identify which one antihypertensive drug will improve pregnancy outcome and fetal safety.
- The confusion exists because data suggesting women with chronic hypertension, treated or untreated, are at increased risk of congenital malformations and/or particular cardiac malformations, compared to normotensive women.

Treatment Options

- Drugs to be discussed have an acceptable safety profile in pregnancy.
- The choice of drug depends on the severity of hypertension and the route of administration:
  - Parenteral
  - Oral

Choice of Drug and Dose

- Acute management of severe hypertension
- Parenteral therapy
- Longer-term BP control during expectant management of severe preeclampsia

Acute Therapy
First-line agents for treatment of severe hypertension:

- Labetalol
- Hydralazine
- Nifedipine is an acceptable alternative to above [135].

Treatment with first line agents should be expeditious and occur as soon as possible within 30-60 min of confirmed severe hypertension to reduce the risk of maternal stroke [159].



Labetalol

- First-line therapy because it is:
  - Effective
  - Has a rapid onset of action
  - A good safety profile

Begin with 20mg intravenously (IV) over 2 minutes followed at 10-minute intervals by doses 20mg to 80mg, up to a maximum total cumulative dose of 220mg.

Labetalol should not be used in women with asthma, heart disease, or congestive heart failure (CHF) [159].

Click the I.V. bag to see types of treatment.



Hydralazine

Begin with 5mg IV over 1 to 2 minutes:

- If BP goal is not achieved within 20 minutes
- Give a 5 to 10mg bolus
- The maximum bolus dose is 20mg

If a total dose of 30mg does not achieve optimal BP control, another agent should be used.

The fall in BP begins within 10 to 30 minutes and lasts for 2 to 4 hours.

Click the I.V. bag to see types of treatment.



Nifedipine - Calcium Channel Blocker (CCB)

Immediate release oral nifedipine capsules should be administered orally and not punctured or otherwise administered sublingually [159].

Sustained release 30mg and immediate release nicardipine are options:

- Nicardipine can be administered IV
- There is limited experience with these drugs in comparison to labetalol and hydralazine.

Target BP reached within 23 mins in 70% of women with severe hypertension and 91% reach target within 130 mins.

Click the I.V. bag to see types of treatment.



Nitroglycerin

A good option for treatment of hypertension associated with pulmonary edema [137].

Administer 5mcg/min IV and gradually increase every 3 to 5 minutes to maximum dose of 100mcg/min.

Click here to see more information.



Rarely is BP not controlled with the drugs discussed previously.

Options for second-line therapy include Labetalol or Nicardipine via IV infusion pump [136].

Nitroprusside is administered as a last resort.

Utilizing the anesthesia team may be needed for central line monitoring and drugs utilized by their team to control BP (ie propofol, esmolol) if these typical measures fail.

Long-term Oral Therapy

May be indicated in preeclamptic women with severe hypertension remote from term when they are:

- Stabilized
- Not delivered immediately

Oral antihypertensive therapy is often indicated for these patients.

- Options for oral antihypertensive therapy are the same as for women with preexisting hypertension
  - Methyldopa or Labetalol
  - Nifedipine can be added as either a 2nd or 3rd line treatment

Target BP

- Systolic 130 to 150mmHg
- Diastolic 80 to 100mmHg

How quickly the BP should be brought to safe levels is controversial.

- Cerebral, myocardial ischemia or infarction can be induced by aggressively reducing the BP.
- It is reasonable to reduce the mean arterial pressure by no more than 25% over two hours and achieving a target of 130-150mmHg systolic and 80-100mmHg diastolic [137].
- Appropriate and prompt management of severe systolic and severe diastolic hypertension is required to reduce risk and have successful, safe clinical outcomes for women with preeclampsia or eclampsia [159].
- There is mounting evidence that patient outcomes improve when standardization of care occurs [159]. A sample set of standard orders follow.
- Adverse maternal outcomes have been reduced when introducing standardization of evidence based clinical guidelines for the management of patients with preeclampsia and eclampsia [159].

MAGNESIUM SULFATE

- Given for the prevention and treatment of seizures in women with preeclampsia and eclampsia.
- As a side note: prolonged antepartum therapy (more than 5 to 7 days) in women with preterm labor has been associated with adverse effects on fetal bones.
- A loading dose of 6 grams intravenous over 15-20 minutes followed by 2 grams per hour as a continuous infusion is the most common regimen [140-143].
- An alternative regimen is 5 grams intramuscularly into each buttock (total of 10 grams) followed by 5 grams intramuscularly every 4 hours.
- A clear threshold concentration has not been determined but there is a recommendation based on retrospective data to help insure the prevention of convulsions with a therapeutic range of 4.8 - 8.4mg/dL (2-3.5mmol/L) [144].
- Loading doses less than 6 grams are more likely to result in subtherapeutic magnesium levels (less than 4.5mg/dL) [142,145].

MAGNESIUM SULFATE

- Since magnesium sulfate is excreted by the kidneys, dosing should be adjusted in women with renal insufficiency (defined as a serum creatinine greater than 1.0mg/dL).
- Such women should receive a standard loading dose (since their volume of distribution is not altered), but a reduced maintenance dose (1 gram per hour or no maintenance dose if the serum creatinine is greater than 2.5mg/dL) and close monitoring of their serum magnesium level every 6 hours or by clinical assessment every 1 to 2 hours.
- The maintenance phase is given only if a patellar reflex is present (loss of reflexes being the first manifestation of symptomatic hypermagnesemia), respirations exceed 12 per minute, and the urine output exceeds 100mL per 4 hours.
- Following serum magnesium levels is not required if the woman's clinical status is closely monitored for evidence of potential magnesium toxicity.
- The maintenance dose should be decreased if there is clinical evidence of magnesium toxicity.

MAGNESIUM SULFATE

Duration of Therapy:

- Magnesium sulfate is usually continued for 24 hours postpartum [142].
- Timing of drug discontinuation has been arbitrary; no high quality data exists to guide therapy.
- In women who have nonsevere preeclampsia, discontinuation of therapy after 12 hours may be safe [146].
- In women with severe preeclampsia or eclampsia, seizure prophylaxis is generally continued for 24 to 48 hours postpartum, after which the risk of recurrent seizures is low.
- Diuresis (greater than 4L/day) is believed to be the most accurate clinical indicator of resolution of preeclampsia/eclampsia, but is not a guarantee against the development of seizures [147].

Mechanism of Anticonvulsant Action:

- The mechanism for the anticonvulsant effects of magnesium sulfate has not been clearly defined.
- The primary effect is thought to be central.
- Another theory is that it promotes vasodilatation of constricted cerebral vessels by opposing calcium-dependent arterial vasospasm, thereby reducing cerebral barotrauma [148].

MAGNESIUM SULFATE

Complications and Side Effects:

- Rapid infusion of magnesium sulfate causes diaphoresis, flushing, and warmth, probably related to peripheral vasodilation and a drop in blood pressure.
- Nausea, vomiting, headache, muscle weakness, visual disturbances, and palpitations can also occur.
- Dyspnea or chest pain may be symptoms of pulmonary edema, which is a rare side effect.
- Magnesium toxicity is uncommon in women with good renal function [149].

Toxicity is Related to Serum Magnesium Concentration:

- Loss of DTR occurs at 7 to 10mEq/L (8.5 to 12mg/dL or 3.5 to 5.0mmol/L).
- Respiratory paralysis at 10 to 13mEq/L (12 to 16mg/dL or 5.0 to 6.5mmol/L).
- Cardiac conduction is altered at >15mEq/L (>18mg/dL or >7.5mmol/L).
- Cardiac arrest occurs at >25mEq/L (>30mg/dL or >12.5mmol/L) [150].
- Calcium gluconate (1 gram IV over 5 to 10 minutes) should be administered only to counteract life-threatening symptoms of magnesium toxicity, such as cardiorespiratory compromise.

MAGNESIUM SULFATE

- Magnesium sulfate is contraindicated in women with myasthenia gravis since it can precipitate a severe myasthenic crisis.
- Neuromuscular blockade and hypotension due to concurrent use of magnesium sulfate and calcium channel blockers have been described in case reports, but the risk appears to be minimal [151].
- Although magnesium sulfate is a weak tocolytic, labor duration does not appear to be affected by magnesium sulfate administration [152].
- The risk of postpartum hemorrhage (PPH), possibly related to uterine atony from magnesium's tocolytic effects, was slightly increased in one trial [153].
- When a patient is therapeutic on magnesium sulfate and has a seizure, the first recommendation is an additional loading dose of magnesium sulfate 2g IV over five minute. If she continues to have seizure activity, alternative anti-convulsants should be considered:
  - Lorazepam 4mg IV over 2-5 minutes (repeating in 5-15 min prn) to maximum of 8mg in 12 hours
  - Diazepam 5-10mg IV slosly (repeating Q15 minutes up to 30mg)
  - Midazolam 1-2mg IV (may repeat in 5-10 minutes)
  - Phenytoin 1000mg IV over 20 minutes
  - iInvolvement of the anesthesia team for further options [163]

ACOG | SOGC | NICE | AHA/ASA

First-Line Therapy

- Labetalol
- Nifedipine
- Methyldopa
    - Methyldopa has been widely used in pregnant women but is only a mild antihypertensive agent and has a slow onset of action (3-6 hours)

Avoiding:

- Angiotensin-converting enzyme inhibitors
- Angiotensin receptor blockers
- Renin inhibitors
- Mineralocorticoid receptor antangonists

Treatment Goal: BP between 120/80 to 160/105mmHg.

Click the grey arrow for more information.

Click the tabs to see recommendations.

ACOG | SOGC | NICE | AHA/ASA

ACOG Committee Opinion on emergent therapy acute onset of severe hypertension in pregnancy and postpartum recommends treatment when:

- Severe systolic >160mmHg
- Severe diastolic >110mmHg
- Or both

To achieve BP of 140-150/90-100mmHg [138].

ACOG Committee Opinion on acute onset of severe hypertension in pregnancy and postpartum ***recommends first-line treatment with***:

- Labetalol
- Hydralazine
- Oral Nifedipine

Recommend using short-acting preparation of oral nifedipine.

Click the tabs to see recommendations.

ACOG | SOGC | NICE | AHA/ASA

The Society of Obstetricians and Gynaecologists of Canada (SOGC) guidelines recommend ***antihypertensive treatment for new onset:***

- Systolic BP >160mmHg or
- Diastolic BP >110mmHg

Goal BP <160/110mmHg [154].

Click the tabs to see recommendations.

ACOG | SOGC | NICE | AHA/ASA

The National Institute for Health and Clinical Excellence (NICE) recommends:

- Pregnant women with uncomplicated chronic hypertension maintain BP lower than 150/100mmHg [155].
- Women with gestational hypertension or preeclampsia treatment begins when BP > 150/100mmHg with goal systolic BP <150mmHg and diastolic BP 80-100mmHg.

Click the tabs to see recommendations.

ACOG | SOGC | NICE | AHA/ASA

AHA/ASA Made These Recommendations for Severe Hypertension in Pregnancy:

- Treat with medications such as:
  - Methyldopa
  - Labetalol
  - Nifedipine
- Treat moderate hypertension to decrease the risk of:
  - Severe hypertension
  - Stroke

Click the tabs to see recommendations.

Common Order Set for Severe Hypertension

1. Notify physician if systolic BP measurement is greater than or equal to 160mmHg or if diastolic BP measurement is greater than or equal to 110mmHg.
2. Fetal surveillance if undelivered and fetus is viable.
3. If severe BP elevations persist for 15 minutes or longer administer labetalol 20mg IV over 2 minutes.
4. Repeat BP measurements in 10 minutes and record results.
5. If either BP threshold is still exceeded, administer labetalol 40mg over 2 minutes.
6. If BP is below threshold, continue BP monitoring closely. Repeat BP measurement in 10 minutes and record results.
7. If either BP threshold is still exceeded, administer labetalol 80mg IV over 2 minutes. If BP is below threshold, continue to monitor BP closely.
8. Repeat BP measurement in 10 minutes and record results.
9. If either BP threshold is still exceeded, administer hydralazine 10mg IV over 2 minutes. If BP is below threshold, continue to monitor BP closely.
10. Repeat BP measurement in 10 minutes and record results.
11. If either BP threshold is still exceeded, obtain emergency consultation from Maternal Fetal Medicine (MFM), Internal Medicine (IM), anesthesia or Critical Care subspecialty.
12. Give specific antihypertensive meds per order.
13. Once BP thresholds are achieved repeat BP measurements every 10 minutes for an hour, then every 15 minutes for an hour, then every 30 minutes for an hour, then every hour for 4 hours [156].

Multi-organ involvement may result in fetal, perinatal and maternal morbidity and mortality [157].

When preeclampsia occurs in women, they are at increased risk for chronic hypertension, renal vascular resistance, and reduced renal flow [159].

Maternal complications include but are not limited to:

- Stroke
- Pulmonary edema
- Hepatic failure
- Jaundice
- Eclampsia

Women developing eclampsia are at great risk for:

- Maternal death
- Need for assisted ventilation
- Adult respiratory distress syndrome (ARDS)
- Acute renal failure
- Embolism
- Placenta abruption
- Acute renal failure [159]
- PRES

Fetal complications

- Oligohydramnios
- Fetal growth restriction
  - Noted in up to 30% of fetus' of women with preeclampsia
- Birth weights <10th percentiles
- Metabolic acidosis
- APGAR score <3 at 5 minutes
- Umbilical artery pH <7
- Positive pressure ventilation (PPV) for <5 minutes

Complications That May Occur When Severe Preeclamapsia is Diagnosed:

- Fetal death.
- Preexisting hypertension and gestational hypertension doubles the risk of stillbirth.
- Preeclampsia triples the risk of stillbirth.
- Eclampsia increases risks for death, RDS, and small for gestational age (SGA) infant [159].
- The rate of stillbirth in hypertension disorders has dropped for pregnancies between 20-39 weeks gestation over the past decade [160].

Although, in pregnancy, preeclampsia is the most common cause of:

- Hypertension
- Thrombocytopenia
- Liver abnormalities
- Renal abnormalities

Other health care conditions should be considered and excluded:

- Acute fatty liver of pregnancy (AFLP)
- Thrombotic thrombocytopenic purpura (TTP)
- Systemic Lupus Erythematosus (SLE) exacerbation

The California Maternal Quality Care Collaborative developed a tool to help differentiate between these disorders. It is a free download from their website [163].

Table 5. Differentiation between Preeclampsia, HELLP Syndrome, Acute Fatty Liver Disease of Pregnancy (AFLD), Thrombotic Thrombocytopenia Purpura (TTP), Hemolytic Uremia Syndrome (HUS) *

	Plts	LFTs	Bili	Cr	LDH	Glu	DIC	CNS
Preeclampsia	±	±	±	±	±	→	±	±
HELLP	↓/↓↓	↑↑	↑	±	↑	→	±	±
AFLD	↓↓	↑↑	↑↑↑	↑	↑	↓↓↓	↑↑↑	±
TTP	↓↓↓	↑	↑	↑	↑↑	→	±	++
HUS	↓	↑↑	↑↑	↑↑↑	↑	→	±	±

AFLD: Acute Fatty Liver Disease of Pregnancy; TTP: Thrombotic Thrombocytopenic Purpura; HUS: Hemolytic Uremia Syndrome; Plts: platelet count; LFTs: liver function test; Bili: total bilirubin level; LDH: Lactate Dehydrogenase; Glu: glucose; DIC: Disseminated Intravascular Coagulation; CNS: Central Nervous System symptoms (confusion, visual changes, headache)

*Arrows represent relative changes: one arrow equals some increase; two arrows indicate moderate increase, and three arrows equal very high increase.

Lyndon A, Lagrew D, Shields L, Main E, Cape V. Improving Health Care Response to Obstetric Hemorrhage. (California Maternal Quality Care Collaborative Toolkit to Transform Maternity Care) Developed under contract #11-10006 with the California Department of Public Health; Maternal, Child and Adolescent Health Division; Published by the California Maternal Quality Care Collaborative, 3/17/15. Reprinted with permission.

Another issue with maternal morbidity and mortality arises from lack of communication. Misdiagnosis and denial of severity of women's illness along with delays or failures in treatment are key factors contributing to fatal outcomes. Lack of listening skills or responsiveness to concern and failure in communication including silence in the face of clinical concern are likely to have contributed to delays, misdiagnosis, and treatment failures.

Teams are found to be effective with collective monitoring, crosschecking one another, and clinical processes in place to proactively identify potential problems. Empowering all staff to "stop the line" or formally interrupt the plan of care and check safety when they observe potential for harm. Listening to a peer whether or not they agree and establishing strategies for communication and teamwork will help to build trust in these complex settings.

There are numerous tools available to help build better communication within a unit. Maternal 911 in Action has a module on Psychological Safety that will be helpful for your team. Please reach out to your facilities leadership if you feel further work is needed, be a part of the solution. Do not remain silent [163].


A thorough history, physical exam, and data collection should be completed in a timely fashion upon admission of any pregnant woman.
The ability to predict preeclampsia is limited.
Accurate identification of women at risk, early diagnosis, and prompt management can improve outcomes.


Consideration for implementing a Preeclampsia Early Recognition Tool (PERT) is detrimental to maternal and fetal health. Please review the PERT at this link:
https://www.pdffiller.com/101064292-2036pdf-Preeclampsia-Early-Recognition-Tool-PERT-Publication-2036-Preeclampsia-Early-Recognition-Tool-PERT-Publication-2036-health-ny-
Conclusion Cont'd

Congratulations!

You have successfully completed this module.

Click on the above 'X' to take the post-test for this course.
If you do not attain a passing score after two attempts at the post-test the entire program must be repurchased.

1. Abalos, E., Cuesta, C., Grosso, A. L., Chou, D., Say, L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2013 Sep;170(1):1-7. Epub 2013 Jun 7.

2. Ananth, C.V., Keyes, K. M., Wapner, R. J. Pre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis. BMJ. 2013;347:f6564.

3. Lisonkova, S., Sabr, Y., Mayer, C., Young,C., Skoll, A., Joseph, K. S. Maternal morbidity associated with early-onset and late-onset preeclampsia. Obstet Gynecol. 2014 Oct;124(4):771-81.

4. Sibai, B. M., Magnesium sulfate prophylaxis in preeclampsia: Lessons learned from recent trials. Am J Obstet Gynecol. 2004;190(6):1520.

5. Douglas, K. A., Redman, C.W. Eclampsia in the United Kingdom. BMJ. 1994;309(6966):1395.

6. Tuffnell, D. J., Jankowicz, D., Lindow, S. W., Lyons, G., Mason, G. C., Russell, I. F., Walker, J. J., Yorkshire Obstetric Critical Care Group. Outcomes of severe pre-eclampsia/eclampsia in Yorkshire 1999/2003. JOG. 2005;112(7):875.

7. Zwart, J. J., Richters, A., Ory, F., de Vries, J. I., Bloemenkamp, K. W., van Roosmalen, J. Eclampsia in the Netherlands. Obstet Gynecol. 2008;112(4):820.

8. Liu, S., Joseph, K. S., Liston, R. M., Bartholomew, S., Walker, M., León, J. A., Kirby, R. S., Sauve, R., Kramer, M. S. Incidence, risk factors, and associated complications of eclampsia. Obstet Gynecol. 2011;118(5):987.

9. Tan, K. H., Kwek, K., Yeo, G.S. Epidemiology of pre-eclampsia and eclampsia at the KK Women's and Children's Hospital, Singapore. Singapore Med J. 2006;47(1):48.

10. Fong, A., Chau, C. T., Pan, D., Ogunyemi, D. A. Clinical morbidities, trends, and demographics of eclampsia: a population-based study. Am J Obstet Gynecol. 2013;209(3):229.e1.

11. Geographic variation in the incidence of hypertension in pregnancy. World Health Organization International Collaborative Study of Hypertensive Disorders of Pregnancy. Am J Obstet Gynecol. 1988;158(1):80.

12. Eke, A. C., Ezebialu, I. U., Okafor, C. Presentation and outcome of eclampsia at a tertiary center in South East Nigeria--a 6-year review. Hypertens Pregnancy. 2011;30(2):125.

13. Miguil, M., Chekairi, A. Eclampsia, study of 342 cases. Hypertens Pregnancy. 2008;27(2):103.

14. Chang J, Elam-Evans LD, Berg CJ, Herndon J, Flowers L, Seed KA, Syverson CJ. Pregnancy-related mortality surveillance--United States, 1991--1999. MMWR Surveill Summ. 2003;52(2):1.

15. Main EK. Maternal mortality: new strategies for measurement and prevention. Curr Opin Obstet Gynecol. 2010 Dec;22(6):511-6.

16. MacKAy AP, Berg CJ, Liu X, Duran C, Hoyert DL. Changes in pregnancy mortality ascertainment: United States, 1999-2005. Obstet Gynecol. 2011;118(1):104.

17. Livingston JC, Livingston LW, Ramsey R, Mabie BC, Sibai BM. Magnesium sulfate in women with mild preeclampsia: a randomized controlled trial. Obstet Gynecol. 2003;101(2):217.

18. MacKay AP, Berg CJ, Atrash HK. Pregnancy-related mortality from preeclampsia and eclampsia. Obstet Gynecol. 2001;97(4):533.

19. Schutte JM, Steegers EA, Schuitemaker NW, Santema JG, de Boer K, Pel M, Vermeulen G, Visser W, van Roosmalen J, Netherlands Maternal Mortality Committee. Rise in maternal mortality in the Netherlands. BJOG. 2010;117(4):399.

20. Moore-Maxwell CA, Robboy SJ. Placental site trophoblastic tumor arising from antecedent molar pregnancy. Gynecol Oncol. 2004;92(2):708.

21. Nugent CE, Punch MR, Barr M Jr, LeBlanc L, Johnson MP, Evans MI. Persistence of partial molar placenta and severe preeclampsia after selective termination in a twin pregnancy. Obstet Gynecol. 1996;87(5 Pt 2):829.

22. Matsuo K, Kooshesh S, Dinc M, Sun CC, Kimura T, Baschat AA. Late postpartum eclampsia: report of two cases managed by uterine curettage and review of the literature. Am J Perinatol. 2007;24(4):257.

23. Kaufmann P, Black S, Huppertz B. Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol Reprod. 2003 Jul;69(1):1-7. Epub 2003 Mar 5.

24. Pijnenborg R, Vercruysse L, Hanssens M. The uterine spiral arteries in human pregnancy: facts and controversies. Placenta. 2006 Sep;27(9-10):939-58. Epub 2006 Feb 20.

25. Robertson WB, Brosens I, Dixon HG. The pathological response of the vessels of the placental bed to hypertensive pregnancy. J Pathol Bacteriol. 1967;93(2):581.

26. Gerretsen G, Huisjes HJ, Elema JD. Morphological changes of the spiral arteries in the placental bed in relation to pre-eclampsia and fetal growth retardation. Br J Obstet Gynaecol. 1981;88(9):876.

27. Brosens IA, Robertson WB, Dixon HG. The role of the spiral arteries in the pathogenesis of preeclampsia. Obstet Gynecol Annu. 1972;1:177.

28. Zhou Y, Damsky CH, Fisher SJ. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? J Clin Invest. 1997;99(9):2152.

29. Robertson WB, Brosens I, Dixon HG. The pathological response of the vessels of the placental bed to hypertensive pregnancy. J Pathol Bacteriol. 1967;93(2):581.

30. Gerretsen G, Huisjes HJ, Elema JD. Morphological changes of the spiral arteries in the placental bed in relation to pre-eclampsia and fetal growth retardation. Br J Obstet Gynaecol. 1981;88(9):876.

31. Khong TY, De Wolf F, Robertson WB, Brosens I. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol. 1986;93(10):1049.

32. De Wolf F, Robertson WB, Brosens I. The ultrastructure of acute atherosis in hypertensive pregnancy. Am J Obstet Gynecol. 1975;123(2):164.

33. Makris A, Thornton C, Thompson J, Thomson S, Martin R, Ogle R, Waugh R, McKenzie P, Kirwan P, Hennessy A. Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int. 2007;71(10):977.

34. Wang X, Athayde N, Trudinger B. A proinflammatory cytokine response is present in the fetal placental vasculature in placental insufficiency. Am J Obstet Gynecol. 2003;189(5):1445.

35. Redman CW, Sargent IL. Preeclampsia and the systemic inflammatory response. Semin Nephrol. 2004;24(6):565.

36. Roberts JM, Speer P. Antioxidant therapy to prevent preeclampsia. Semin Nephrol. 2004;24(6):557.

37. Yinon Y, Nevo O, Xu J, Many A, Rolfo A, Todros T, Post M, Caniggia I. Severe intrauterine growth restriction pregnancies have increased placental endoglin levels: hypoxic regulation via transforming growth factor-beta 3. Am J Pathol. 2008;172(1):77.

38. Rusterholz C, Hahn S, Holzgreve W. Role of placentally produced inflammatory and regulatory cytokines in pregnancy and the etiology of preeclampsia. Semin Immunopathol. 2007;29(2):151.

39. Maynard S, Epstein FH, Karumanchi SA. Preeclampsia and angiogenic imbalance. Annu Rev Med. 2008;59:61.

40. Ilekis JV, Reddy UM, Roberts JM. Preeclampsia--a pressing problem: an executive summary of a National Institute of Child Health and Human Development workshop. Reprod Sci. 2007;14(6):508.

41. Cunningham FG, Lindheimer MD. Hypertension in pregnancy. N Engl J Med. 1992;326(14):927.

42. American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists'Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122(5):1122.

43. Rafik Hamad R, Larsson A, Pernow J, Bremme K, Eriksson MJ. Assessment of left ventricular structure and function in preeclampsia by echocardiography and cardiovascular biomarkers. J Hypertens. 2009 Nov;27(11):2257-64.

44. Shahul S, Rhee J, Hacker MR, Gulati G, Mitchell JD, Hess P, Mahmood F, Arany Z, Rana S, Talmor D. Subclinical left ventricular dysfunction in preeclamptic women with preserved left ventricular ejection fraction: a 2D speckle-tracking imaging study. Circ Cardiovasc Imaging. 2012;5(6):734.

45.Hankins GD, Wendel GD Jr, Cunningham FG, Leveno KJ. Longitudinal evaluation of hemodynamic changes in eclampsia. Am J Obstet Gynecol. 1984;150(5 Pt 1):506.

46. Cotton DB, Lee W, Huhta JC, Dorman KF. Hemodynamic profile of severe pregnancy-induced hypertension. Am J Obstet Gynecol. 1988;158(3 Pt 1):523.

47. Phelan JP, Yurth DA. Severe preeclampsia. I. Peripartum hemodynamic observations. Am J Obstet Gynecol. 1982;144(1):17.

48. Clark SL, Greenspoon JS, Aldahl D, Phelan JP. Severe preeclampsia with persistent oliguria: management of hemodynamic subsets. Am J Obstet Gynecol. 1986;154(3):490.

49. Mabie WC, Ratts TE, Sibai BM. The central hemodynamics of severe preeclampsia. Am J Obstet Gynecol. 1989;161(6 Pt 1):1443.

50. Melchiorre K, Sutherland GR, Baltabaeva A, Liberati M, Thilaganathan B. Maternal cardiac dysfunction and remodeling in women with preeclampsia at term. Hypertension. 2011;57(1):85.

51. Nabatian S, Quinn P, Brookfield L, Lakier J. Acute coronary syndrome and preeclampsia. Obstet Gynecol. 2005;106(5 Pt 2):1204.

52. Fleming SM, O'Gorman T, Finn J, Grimes H, Daly K, Morrison JJ. Cardiac troponin I in pre-eclampsia and gestational hypertension. BJOG. 2000;107(11):1417.

53. Joyal D, Leya F, Koh M, Besinger R, Ramana R, Kahn S, Jeske W, Lewis B, Steen L, Mestril R, Arab D. Troponin I levels in patients with preeclampsia. Am J Med. 2007;120(9):819.e13.

54. Benedetti TJ, Kates R, Williams V. Hemodynamic observations in severe preeclampsia complicated by pulmonary edema. Am J Obstet Gynecol. 1985;152(3):330.

55. Ginsberg JM, Chang BS, Matarese RA, Garella S. Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med. 1983;309(25):15.

56. Schwab SJ, Christensen RL, Dougherty K, Klahr S. Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples. Arch Intern Med. 1987;147(5):943.

57. Abitbol C, Zilleruelo G, Freundlich M, Strauss J. Quantitation of proteinuria with urinary protein/creatinine ratios and random testing with dipsticks in nephrotic children. J Pediatr. 1990;116(2):243.

58. Steinhäuslin F, Wauters JP. Quantitation of proteinuria in kidney transplant patients: accuracy of the urinary protein/creatinine ratio. Clin Nephrol. 1995;43(2):110.

59. Chitalia VC, Kothari J, Wells EJ, Livesey JH, Robson RA, Searle M, Lynn KL. Cost-benefit analysis and prediction of 24-hour proteinuria from the spot urine protein-creatinine ratio. Clin Nephrol. 2001;55(6):436.

60. Zelmanovitz T, Gross JL, Oliveira J, de Azevedo MJ. Proteinuria is still useful for the screening and diagnosis of overt diabetic nephropathy. Diabetes Care. 1998;21(7):1076.

61. Zelmanovitz T, Gross JL, Oliveira JR, Paggi A, Tatsch M, Azevedo MJ. The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy. Diabetes Care. 1997;20(4):516.

62. Bakker AJ. Detection of microalbuminuria. Receiver operating characteristic curve analysis favors albumin-to-creatinine ratio over albumin concentration. Diabetes Care. 1999;22(2):307.

63. Shidham G, Hebert LA. Timed urine collections are not needed to measure urine protein excretion in clinical practice. Am J Kidney Dis. 2006;47(1):8.

64. O'brien JR, Bergauer JM, Jacques NK, Sibai BM. Mild gestational hypertension remote from term: progression and outcome. Am J Obstet Gynecol. 2001;184(5):979.

65. Buchbinder A, Sibai BM, Caritis S, Macpherson C, Hauth J, Lindheimer MD, Klebanoff M, Vandorsten P, Landon M, Paul R, Miodovnik M, Meis P, Thurnau G, National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia. Am J Obstet Gynecol. 2002;186(1):66.

66. Moran P, Lindheimer MD, Davison JM. The renal response to preeclampsia. Semin Nephrol. 2004;24(6):588.

67. Lam C, Lim KH, Kang DH, Karumanchi SA. Uric acid and preeclampsia. Semin Nephrol. 2005 Jan;25(1):56-60.

68. S, Ismail KM, Sharp S, Coomarasamy A, Khan KS, Tests in Prediction of Pre-eclampsia Severity review group. Accuracy of serum uric acid in predicting complications of pre-eclampsia: a systematic review. BJOG. 2006;113(4):369.

69. Cnossen JS, de Ruyter-Hanhijärvi H, van der Post JA, Mol BW, Khan KS, ter Riet G. Accuracy of serum uric acid determination in predicting pre-eclampsia: a systematic review. Acta Obstet Gynecol Scand. 2006;85(5):519.

70. Livingston JR, Payne B, Brown M, Roberts JM, CôtéAM, Magee LA, von Dadelszen P. Uric Acid as a predictor of adverse maternal and perinatal outcomes in women hospitalized with preeclampsia. J Obstet Gynaecol Can. 2014 Oct;36(10):870-7.

71. Stillman IE, Karumanchi SA. The glomerular injury of preeclampsia. J Am Soc Nephrol. 2007;18(8):2281.

72. Henao DE, Mathieson PW, Saleem MA, Bueno JC, Cadavid A. A novel renal perspective of preeclampsia: a look from the podocyte. Nephrol Dial Transplant. 2007 May;22(5):1477. Epub 2007 Jan 18.

73. Strevens H, Wide-Swensson D, Hansen A, Horn T, Ingemarsson I, Larsen S, Willner J, Olsen S. Glomerular endotheliosis in normal pregnancy and pre-eclampsia. BJOG. 2003;110(9):831.

74. Burrows RF, Hunter DJ, Andrew M, Kelton JG. A prospective study investigating the mechanism of thrombocytopenia in preeclampsia. Obstet Gynecol. 1987 Sep;70(3 Pt 1):334-8.

75. Prieto JA, Mastrobattista JM, Blanco JD. Coagulation studies in patients with marked thrombocytopenia due to severe preeclampsia. Am J Perinatol. 1995 May;12(3):220-2.

76. Minakami H, Oka N, Sato T, Tamada T, Yasuda Y, Hirota N. Preeclampsia: a microvesicular fat disease of the liver? Am J Obstet Gynecol. 1988;159(5):1043.

77. Dani R, Mendes GS, Medeiros Jde L, Péret FJ, Nunes A. Study of the liver changes occurring in preeclampsia and their possible pathogenetic connection with acute fatty liver of pregnancy. Am J Gastroenterol. 1996;91(2):292.

78. Walters BN, Preeclamptic angina--a pathognomonic symptom of preeclampsia. Hypertens Pregnancy. 2011;30(2):117

79. Shah AK, Rajamani K, Whitty JE. Eclampsia: a neurological perspective. J Neurol Sci. 2008;271(1-2):158.

80. Shah, AK, Whitty, J. Characteristics of headache in women with eclampsia. Neurology. 1999; 52(Suppl 2):A285.

81. Errera MH, Kohly RP, da Cruz L. Pregnancy-associated retinal diseases and their management. Surv Ophthalmol. 2013 Mar;58(2):127-42.

82. Schultz KL, Birnbaum AD, Goldstein DA. Ocular disease in pregnancy. Curr Opin Ophthalmol. 2005;16(5):308.

83. Dinn RB, Harris A, Marcus PS. Ocular changes in pregnancy. Obstet Gynecol Surv. 2003;58(2):137.

84. Roos NM, Wiegman MJ, Jansonius NM, Zeeman GG. Visual disturbances in (pre)eclampsia. Obstet Gynecol Surv. 2012;67(4):242.

85. Cunningham FG, Fernandez CO, Hernandez C. Blindness associated with preeclampsia and eclampsia. Am J Obstet Gynecol. 1995;172(4 Pt 1):1291.

86. Carpenter F, Kava HL, Plotkin D. The development of total blindness as a complication of pregnancy. Am J Obstet Gynecol. 1953;66(3):641.

87. Richards A, Graham D, Bullock R. Clinicopathological study of neurological complications due to hypertensive disorders of pregnancy. J Neurol Neurosurg Psychiatry. 1988;51(3):416.

88. Drislane FW, Wang AM. Multifocal cerebral hemorrhage in eclampsia and severe pre-eclampsia. J Neurol. 1997;244(3):194.

89. Morriss MC, Twickler DM, Hatab MR, Clarke GD, Peshock RM, Cunningham FG. Cerebral blood flow and cranial magnetic resonance imaging in eclampsia and severe preeclampsia. Obstet Gynecol. 1997;89(4):561.

90. Zeeman GG. Neurologic complications of pre-eclampsia. Semin Perinatol. 2009 Jun;33(3):166-72.

91. Zunker P, Ley-Pozo J, Louwen F, Schuierer G, Holzgreve W, Ringelstein EB. Cerebral hemodynamics in pre-eclampsia/eclampsia syndrome. Ultrasound Obstet Gynecol. 1995 Dec;6(6):411-5.

92. Eastabrook G, Brown M, Sargent I. The origins and end-organ consequence of pre-eclampsia. Best Pract Res Clin Obstet Gynaecol. 2011 Aug;25(4):435-47. Epub 2011 Mar 1.

93. Crovetto F, Somigliana E, Peguero A, Figueras F. Stroke during pregnancy and pre-eclampsia. Curr Opin Obstet Gynecol. 2013 Dec;25(6):425-32.

94. Spracklen CN, Smith CJ, Saftlas AF, Robinson JG, Ryckman KK. Maternal hyperlipidemia and the risk of preeclampsia: a meta-analysis. Am J Epidemiol. 2014;180(4):346.

95. Gallos ID, Sivakumar K, Kilby MD, Coomarasamy A, Thangaratinam S, Vatish M. Pre-eclampsia is associated with, and preceded by, hypertriglyceridaemia: a meta-analysis. BJOG. 2013 Oct;120(11):1321-32. Epub 2013 Jul 17.

96. Lynch TA, Dexter SC. Alcoholic Pancreatitis Masquerading as Preeclampsia. Obstet Gynecol. 2015 Dec;126(6):1276-8.

97. Odegård RA, Vatten LJ, Nilsen ST, Salvesen KA, Austgulen R. Preeclampsia and fetal growth. Obstet Gynecol. 2000;96(6):950.

98. Xiong X, Demianczuk NN, Buekens P, Saunders LD. Association of preeclampsia with high birth weight for age. Am J Obstet Gynecol. 2000;183(1):148.

99. Rasmussen S, Irgens LM. Fetal growth and body proportion in preeclampsia. Obstet Gynecol. 2003;101(3):575.

100. Xiong X, Demianczuk NN, Saunders LD, Wang FL, Fraser WD. Impact of preeclampsia and gestational hypertension on birth weight by gestational age. Am J Epidemiol. 2002;155(3):203.

101. Eskild A, Romundstad PR, Vatten LJ. Placental weight and birthweight: does the association differ between pregnancies with and without preeclampsia? Am J Obstet Gynecol. 2009;201(6):595.e1.

102. Vatten LJ, Skjaerven R. Is pre-eclampsia more than one disease? BJOG. 2004;111(4):298.

103. Sohlberg S, Mulic-Lutvica A, Lindgren P, Ortiz-Nieto F, Wikström AK, Wikström J. Placental perfusion in normal pregnancy and early and late preeclampsia: a magnetic resonance imaging study. Placenta. 2014;35(3):202.

104. Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. Am J Obstet Gynecol. 2013 Dec;209(6):544.e1-544.e12. Epub 2013 Aug 22.

105. Harmon QE, Huang L, Umbach DM, Klungsøyr K, Engel SM, Magnus P, Skjærven R, Zhang J, Wilcox AJ. Risk of fetal death with preeclampsia. Obstet Gynecol. 2015;125(3):628.

106. Friedman SA, Schiff E, Kao L, Sibai BM. Neonatal outcome after preterm delivery for preeclampsia. Am J Obstet Gynecol. 1995;172(6):1785.

107. Sibai BM, Mercer BM, Schiff E, Friedman SA. Aggressive versus expectant management of severe preeclampsia at 28 to 32 weeks' gestation: a randomized controlled trial. Am J Obstet Gynecol. 1994;171(3):818.

108. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ. 2005;330(7491):565.

109. Saftlas AF, Olson DR, Franks AL, Atrash HK, Pokras R. Epidemiology of preeclampsia and eclampsia in the United States, 1979-1986. Am J Obstet Gynecol. 1990;163(2):460.

110. Sibai BM, el-Nazer A, Gonzalez-Ruiz A. Severe preeclampsia-eclampsia in young primigravid women: subsequent pregnancy outcome and remote prognosis. Severe preeclampsia-eclampsia in young primigravid women: subsequent pregnancy outcome and remote prognosis.

111. van Rijn BB, Hoeks LB, Bots ML, Franx A, Bruinse HW. Outcomes of subsequent pregnancy after first pregnancy with early-onset preeclampsia. Am J Obstet Gynecol. 2006;195(3):723.

112. Sibai BM, Mercer B, Sarinoglu C. Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis. Am J Obstet Gynecol. 1991;165(5 Pt 1):1408.

113. Gaugler-Senden IP, Berends AL, de Groot CJ, Steegers EA. Severe, very early onset preeclampsia: subsequent pregnancies and future parental cardiovascular health. Eur J Obstet Gynecol Reprod Biol. 2008;140(2):171.

114. Campbell DM, MacGillivray I, Carr-Hill R. Pre-eclampsia in second pregnancy. Br J Obstet Gynaecol. 1985;92(2):131.

115. Xiong X, Fraser WD, Demianczuk NN. History of abortion, preterm, term birth, and risk of preeclampsia: a population-based study. Am J Obstet Gynecol. 2002;187(4):1013.

116. Mogren I, Högberg U, Winkvist A, Stenlund H. Familial occurrence of preeclampsia. Epidemiology. 1999;10(5):518.

117. Cincotta RB, Brennecke SP. Family history of pre-eclampsia as a predictor for pre-eclampsia in primigravidas. Int J Gynaecol Obstet. 1998;60(1):23.

118. Skjaerven R, Vatten LJ, Wilcox AJ, Rønning T, Irgens LM, Lie RT. Recurrence of pre-eclampsia across generations: exploring fetal and maternal genetic components in a population based cohort. BMJ. 2005;331(7521):877.

119. Carr DB, Epplein M, Johnson CO, Easterling TR, Critchlow CW. A sister's risk: family history as a predictor of preeclampsia. Am J Obstet Gynecol. 2005;193(3 Pt 2):965.

120. Treloar SA, Cooper DW, Brennecke SP, Grehan MM, Martin NG. An Australian twin study of the genetic basis of preeclampsia and eclampsia.. Am J Obstet Gynecol. 2001;184(3):374.

121. Esplin MS, Fausett MB, Fraser A, Kerber R, Mineau G, Carrillo J, Varner MW. Paternal and maternal components of the predisposition to preeclampsia. N Engl J Med. 2001;344(12):867.

122. Skjaerven R, Vatten LJ, Wilcox AJ, Rønning T, Irgens LM, Lie RT. Recurrence of pre-eclampsia across generations: exploring fetal and maternal genetic components in a population based cohort. BMJ. 2005;331(7521):877.

123. Lie RT, Rasmussen S, Brunborg H, Gjessing HK, Lie-Nielsen E, Irgens LM. Fetal and maternal contributions to risk of pre-eclampsia: population based study. BMJ. 1998;316(7141):1343.

124. Vikse BE, Irgens LM, Leivestad T, Skjaerven R, Iversen BM. Preeclampsia and the risk of end-stage renal disease. N Engl J Med. 2008;359(8):800.

125. Levine RJ, Vatten LJ, Horowitz GL, Qian C, Romundstad PR, Yu KF, Hollenberg AN, Hellevik AI, Asvold BO, Karumanchi SA. Pre-eclampsia, soluble fms-like tyrosine kinase 1, and the risk of reduced thyroid function: nested case-control and population based study. BMJ. 2009;339:b4336.

126. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295.

127. Giannakopoulos B, Passam F, Ioannou Y, Krilis SA. How we diagnose the antiphospholipid syndrome. Blood. 2009;113(5):985.

128. Lima F, Khamashta MA, Buchanan NM, Kerslake S, Hunt BJ, Hughes GR. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol. 1996;14(2):131.

129. Branch DW, Silver RM, Blackwell JL, Reading JC, Scott JR. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol. 1992;80(4):614.

130. Nevis IF, Reitsma A, Dominic A, McDonald S, Thabane L, Akl EA, Hladunewich M, Akbari A, Joseph G, Sia W, Iansavichus AV, Garg AX. Pregnancy outcomes in women with chronic kidney disease: a systematic review. Clin J Am Soc Nephrol. 2011 Nov;6(11):2587-98. Epub 2011 Sep 22.

131. Bramham K, Briley AL, Seed PT, Poston L, Shennan AH, Chappell LC. Pregnancy outcome in women with chronic kidney disease: a prospective cohort study. Reprod Sci. 2011 Jul;18(7):623-30. Epub 2011 Feb 1.

132. Cassell KA, O'connell CM, Baskett TF. The origins and outcomes of triplet and quadruplet pregnancies in Nova Scotia: 1980 to 2001. Am J Perinatol. 2004 Nov;21(8):439-45.

133. Barron WM, Heckerling P, Hibbard JU, Fisher S. Reducing unnecessary coagulation testing in hypertensive disorders of pregnancy. Obstet Gynecol. 1999;94(3):364.

134. Firoz T, Magee LA, MacDonell K, Payne BA, Gordon R, Vidler M, von Dadelszen P, Community Level Interventions for Pre-eclampsia (CLIP) Working Group. Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review. BJOG. 2014 Sep;121(10):1210-8; discussion 1220. Epub 2014 May 16.

135. Nij Bijvank SW, Duvekot JJ. Nicardipine for the treatment of severe hypertension in pregnancy: a review of the literature. Obstet Gynecol Surv. 2010;65(5):341.

136. Committee on Obstetric Practice. Committee Opinion No. 623: Emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period. Obstet Gynecol. 2015;125(2):521.

137. Visintin C, Mugglestone MA, Almerie MQ, Nherera LM, James D, Walkinshaw S, Guideline Development Group. Management of hypertensive disorders during pregnancy: summary of NICE guidance. BMJ. 2010;341:c2207.

138. American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists'Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122(5):1122.

139. Witlin AG, Sibai BM. Magnesium sulfate therapy in preeclampsia and eclampsia. Obstet Gynecol. 1998;92(5):883.

140. Alexander JM, McIntire DD, Leveno KJ, Cunningham FG. Selective magnesium sulfate prophylaxis for the prevention of eclampsia in women with gestational hypertension. Obstet Gynecol. 2006;108(4):826.

141. Sibai BM. Magnesium sulfate prophylaxis in preeclampsia: Lessons learned from recent trials. Am J Obstet Gynecol. 2004;190(6):1520.

142. Sibai BM, Lipshitz J, Anderson GD, Dilts PV Jr. Reassessment of intravenous MgSO4 therapy in preeclampsia-eclampsia. Obstet Gynecol. 1981;57(2):199.

143. Taber EB, Tan L, Chao CR, Beall MH, Ross MG. Pharmacokinetics of ionized versus total magnesium in subjects with preterm labor and preeclampsia. Am J Obstet Gynecol. 2002;186(5):1017.

144. Sibai BM. Magnesium sulfate prophylaxis in preeclampsia: Lessons learned from recent trials. Am J Obstet Gynecol. 2004;190(6):1520.

145. Ehrenberg HM, Mercer BM. Abbreviated postpartum magnesium sulfate therapy for women with mild preeclampsia: a randomized controlled trial. Obstet Gynecol. 2006;108(4):833.

146. Miles JF Jr, Martin JN Jr, Blake PG, Perry KG Jr, Martin RW, Meeks GR. Postpartum eclampsia: a recurring perinatal dilemma. Obstet Gynecol. 1990;76(3 Pt 1):328.

147. Belfort MA, Clark SL, Sibai B. Cerebral hemodynamics in preeclampsia: cerebral perfusion and the rationale for an alternative to magnesium sulfate. Obstet Gynecol Surv. 2006 Oct;61(10):655-65.

148. Smith JM, Lowe RF, Fullerton J, Currie SM, Harris L, Felker-Kantor E. An integrative review of the side effects related to the use of magnesium sulfate for pre-eclampsia and eclampsia management. BMC Pregnancy Childbirth. 2013 Feb;13(1):34. Epub 2013 Feb 5.

149. Lu JF, Nightingale CH. Magnesium sulfate in eclampsia and pre-eclampsia: pharmacokinetic principles. Clin Pharmacokinet. 2000 Apr;38(4):305-14.

150. Belfort MA, Anthony J, Saade GR, Allen JC Jr, Nimodipine Study Group. A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. N Engl J Med. 2003;348(4):304.

151. Magee LA, Miremadi S, Li J, Cheng C, Ensom MH, Carleton B, CôtéAM, von Dadelszen P. Therapy with both magnesium sulfate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with preeclampsia. Am J Obstet Gynecol. 2005 Jul;193(1):153-63.

152. Szal SE, Croughan-Minihane MS, Kilpatrick SJ. Effect of magnesium prophylaxis and preeclampsia on the duration of labor. Am J Obstet Gynecol. 1999;180(6 Pt 1):1475.

153. Brosens I, Pijnenborg R, Vercruysse L, Romero R. The "Great Obstetrical Syndromes" are associated with disorders of deep placentation. Am J Obstet Gynecol 2011; 204:193.

154. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P, Hypertension Guideline Committee, Magee LA, Audibert F, Bujold E, CôtéAM, Douglas MJ, Eastabrook G, Firoz T, Gibson P, Gruslin A, Hutcheon J, Koren G, Lange I, Leduc L, Logan AG, MacDonell KL, Moutquin JM, Sebbag I. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can. 2014

155. National Collaborating Centre for Women's and Children's Health. Hypertension in pregnancy. The management of hypertensive disorders during pregnancy. London (UK): National Institute for Health and Clinical Excellence (NICE); 2010 Aug. 46 p. (Clinical guideline; no. 107). http://www.guideline.gov/content.aspx?id=24122.

156. Data is from the National Heart, Lung and Blood Institute. The 7the report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure. NIH Publication No 04-5230. Bethesda (MD): NHLBI; 2004.

157. McDonald SD, Malinowski A, Zhou Q, Yusuf S, Devereaux PJ. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J 2008;156(5):918-30.

158. Spaan JJ, Ekhart T, Spaanderman ME, Peeters LL. Remote hemodynamics and renal function in formerly preeclamptic women. Obstet Gynecol 2009;113(4):853-9.

159. Liu S, Joseph KS, Liston RM, Bartholomew S, Walker M, Leon JA, et al. Incidence, risk factors, and associated complications of eclampsia. Obstet Gynecol 2011;118(5):987-94.

160. Ahmad A, Samuelsen S. Hypertensive disorders in pregnancy and fetal death at different gestational lengths: a population study of 2 121 371 pregnancies. BJOG 2012;119(12):1521-8.

161.Tarassenko L, Hann A, Yang D. Integrated monitoring and analysis for early warning of patient deterioration. Br J Anesth. 2006;97:64-68.

162. The Joint Commission. Preventing Maternal Death. Sentinal Event Alert. Issue 44. 2010; http://www.jointcommission.org/sentinal_event_alert_issue_44_preventing_maternal_death. Accessed January 26, 2010.

163. Weblink: file:///C:/Users/becherm/Downloads/CDPH_Approved_Preeclampsia_Toolkit__Errata_v3.5.13.14_with_slideset%20(4).pdf